As of March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs carries a market capitalization of 97.78B, placing it among publicly traded companies globally. Its enterprise value stands at -233.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 97.78B |
| Enterprise Value | -233.80B |
As of March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs has 35.17M shares outstanding.
| Shares Outstanding | 35.17M |
These figures are as of March 31, 2026. The price-to-sales ratio is 6.25, and the price-to-book ratio stands at 0.17.
| PS Ratio | 6.25 |
| PB Ratio | 0.17 |
| P/TBV Ratio | 0.17 |
| P/FCF Ratio | -1.35 |
| P/OCF Ratio | -1.38 |
As of March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs maintains a current ratio of 16.86, meaning it holds 16.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.65, indicating elevated leverage, while an interest coverage ratio of -25.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 16.86 |
| Quick Ratio | 15.09 |
| Debt / Equity | 7.65 |
| Debt / EBITDA | -0.83 |
| Interest Coverage | -25.35 |
Over the twelve months ended March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs posted a negative return on equity (ROE) of -13.75, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.45, reflecting losses generated across the asset base. The company generates approximately 173.74M in revenue per employee across its workforce of 89.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.23 indicates how many times Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -13.75 |
| Return on Assets (ROA) | -12.45 |
| Revenue Per Employee | 173.74M |
| Employee Count | 89.50 |
| Inventory Turnover | 3.23 |
Over the twelve months ended March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs recorded an income tax benefit of -24.80B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -109.13B and -83.46B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -24.80B |
As of the close on November 17, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs's stock has declined approximately 56.29% over the past 52 weeks. The 50-day moving average sits at 2,103.68, while the 200-day moving average is 2,704.57.
| 52-Week Price Change | -56.29% |
| 50-Day Moving Average | 2,103.68 |
| 200-Day Moving Average | 2,704.57 |
Over the twelve months ended March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs generated 15.55B in revenue and converted that into -83.46B in net income, yielding earnings per share of -2,413.08. EBITDA reached -52.34B, while operating income came in at -66.76B.
| Revenue | 15.55B |
| Gross Profit | -33.40B |
| Operating Income | -66.76B |
| Pretax Income | -109.13B |
| Net Income | -83.46B |
| EBITDA | -52.34B |
| EBIT | -66.84B |
| Earnings Per Share (EPS) | -2,413.08 |
As of March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs holds 376.46B in cash and equivalents against 43.70B in total debt, resulting in a net debt position of -281.57B. Total book value stands at 570.11B, with working capital of 395.69B providing operational flexibility.
| Cash & Cash Equivalents | 376.46B |
| Total Debt | 43.70B |
| Net Debt | -281.57B |
| Equity (Book Value) | 570.11B |
| Book Value Per Share | 16,208.47 |
| Working Capital | 395.69B |
Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs produced -70.60B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.50B in capital expenditures, free cash flow totaled -72.10B - equivalent to -2,062.99 per share.
| Operating Cash Flow | -70.60B |
| Capital Expenditures | -1.50B |
| Free Cash Flow | -72.10B |
| FCF Per Share | -2,062.99 |
Over the twelve months ended March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs posted a gross margin of -214.79, reflecting its pricing power and cost economics. The operating margin of -429.37 and net profit margin of -536.74 provide insight into operational efficiency.
| Gross Margin | -214.79 |
| Operating Margin | -429.37 |
| Pretax Margin | -701.85 |
| Profit Margin | -536.74 |
| EBITDA Margin | -336.60 |
These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -74.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 4.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs shareholders.
| Shareholder Yield | 4.06 |
| FCF Yield | -74.21 |
As of March 31, 2026, Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs has an Altman Z-Score of 2.89, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.89 |